Demcizumab (OMP 21M18) is an anti-DLL4 моноклональный антитело. Demcizumab is a мощный ингибитор of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.